Drimmunity Secures $40M Series B Financing to Advance Global Clinical Development of TX-103, a First-in-Class B7-H3 CAR-T Therapy for Solid Tumors

Jul 15, 2025 17:15 CST Updated 17:15

Tcelltech

Developer of Immuno-oncology and Cell Therapy Drugs

Biotechnology Transformation Network: July 15, 2025, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd., a company focused on immunotherapy for solid tumors (Drimmunity / Tcelltech，Hereinafter referred to as: Tuoxin Tiancheng) announced the completion of nearly 40 million US dollars in B-round financing. This round of financing was led by SDIC Venture Capital, with a well-known insurance capital and Hutang Venture Capital following up. It also received strong support from institutions such as Xingye Guoxin Asset Management and Fuzhou Mindu Talent Fund.

The proceeds from this round will be mainly used to support the clinical development of the company’s core pipeline, TX-103, in China and the U.S., the research and development of other pipeline projects, the expansion of the global team, as well as to accelerate the company’s international strategic layout and promote BD cooperation.

Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. was establishedIn April 2017, it is a clinical-stage innovative pharmaceutical company focused on the development of immunotherapy drugs for solid tumors.Founded by pioneers in tumor immunology, Professor Chen Lieping, and expert in immunocyte therapy, Professor Huang Gangxiong. Core pipelineTX-103 is the world's first B7-H3 CAR-T cell therapy product to enter registrational clinical trials and conduct international clinical trials, targeting solid tumors such as recurrent glioblastoma (rGBM).Glioblastoma (GBM) is the most common primary intracranial malignant tumor, with 45,000 and 11,000 new cases annually in China and the United States, respectively. Almost all patients relapse after first-line standard treatment. The median overall survival (mOS) for recurrent patients is only 6-8 months, and the recurrence is more aggressive, with a lack of effective subsequent treatment options, representing a significant unmet clinical need.

TX-103 has demonstrated excellent efficacy and safety in early clinical trials,Can significantly prolong mOS and improve one-year survival rate in rGBM patients., and it is well-tolerated, with the potential to break through the bottleneck of existing therapies. Global Phase I clinical trials are currently underway.

In addition, based on the founding team's deep accumulation and global leadership in tumor immunology, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. is simultaneously developing the next generation of universal-type/In vivo cell therapy and T-cell engager platforms, striving to build a globally leading solid tumor immunotherapy platform company.

-End-

Source: Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.

About Shanjixue She